CYP2C19 genotype-directed P<sub>2</sub>Y<sub>12</sub> inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention.

Indian Heart J · 2021 · PMC8322803 · PMID 34154743

Europe PMC DOI

hedged sentence

0.0970

closest p · 1.9× alpha

0.0970

boldest claim

The sentences

marginally significantp = 0.097so close (0.05 < p ≤ 0.1)

After adjusting for multiple comparisons, there was a marginally significant difference between category 1 and 2 (0% vs. 4.2%; p = 0.097).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.